PharmaShots | Incisive News in 3 Shots

Subscribe Now

CV Risks

AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Patients with Type-2 Diabetes

AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Pat...

January 6, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us